APA (7th ed.) Citation

MG, L., D, O., S, S., LA, S., SQ, W., LH, P., . . . GP, R. (2018). Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. European urology, 74(5), 562. https://doi.org/10.1016/j.eururo.2018.06.020

Chicago Style (17th ed.) Citation

MG, Lawrence, et al. "Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy." European Urology 74, no. 5 (2018): 562. https://doi.org/10.1016/j.eururo.2018.06.020.

MLA (9th ed.) Citation

MG, Lawrence, et al. "Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy." European Urology, vol. 74, no. 5, 2018, p. 562, https://doi.org/10.1016/j.eururo.2018.06.020.